Qube Research & Technologies (QRT)
CYTK icon

Qube Research & Technologies (QRT)’s Cytokinetics CYTK Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,800
Closed -$484K – 4540
2023
Q4 		$484K Buy
+5,800
New +$210K ﹤0.01% 2307

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CYTK Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Cytokinetics (CYTK) stake by 45% in Q1 2026, buying an estimated $15.4M and bringing the position to 779,446 shares worth $51.4M. The position accounts for 0.06% of the portfolio, ranked #420.

Qube Research & Technologies (QRT) first reported a position in CYTK in Q2 2020 and has held it in 15 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Qube Research & Technologies (QRT) held 779,446 shares of Cytokinetics worth $51.4M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 242,169 Cytokinetics shares in Q1 2026, an estimated $15.4M.
  • Cytokinetics made up 0.06% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #420 holding.
  • Qube Research & Technologies (QRT) first reported a position in Cytokinetics in Q2 2020 and has held it in 15 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.